Have your own idea? Try our Stock Screener
Australian (ASX) Clinical Research and Equipment Industry Analysis
UpdatedAug 31, 2026
DataAggregated Company Financials
Companies8
- 7D-5.9%
- 3M17.0%
- 1Y19.5%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 5.9%, driven by Vitrafy Life Sciences declining 11%. Meanwhile, Genetic Signatures actually outperformed within the industry, gaining 18% in the last week. In the past year, the industry has gained 20%. Looking forward, earnings are forecast to grow by 18% annually.
Industry Valuation and Performance
Has the Australian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 31 Aug 2026 | AU$667.6m | AU$254.2m | -AU$44,570,747.00 | 25.5x | -15x | 2.6x |
| Wed, 29 Jul 2026 | AU$607.5m | AU$262.6m | -AU$42,679,164.00 | 23.8x | -14.2x | 2.3x |
| Fri, 26 Jun 2026 | AU$624.6m | AU$262.6m | -AU$42,679,164.00 | 24.9x | -14.6x | 2.4x |
| Sun, 24 May 2026 | AU$491.5m | AU$262.6m | -AU$42,679,164.00 | 20.6x | -11.5x | 1.9x |
| Tue, 21 Apr 2026 | AU$519.4m | AU$262.6m | -AU$42,679,164.00 | 22x | -12.2x | 2x |
| Thu, 19 Mar 2026 | AU$443.0m | AU$262.6m | -AU$42,679,164.00 | 19.1x | -10.4x | 1.7x |
| Sat, 14 Feb 2026 | AU$394.2m | AU$208.0m | -AU$65,085,157.00 | 31x | -6.1x | 1.9x |
| Mon, 12 Jan 2026 | AU$436.3m | AU$206.8m | -AU$83,644,198.00 | 25.9x | -5.2x | 2.1x |
| Wed, 10 Dec 2025 | AU$403.6m | AU$206.8m | -AU$83,644,198.00 | 29.3x | -4.8x | 2x |
| Fri, 07 Nov 2025 | AU$539.0m | AU$273.6m | -AU$76,913,757.00 | 24.2x | -7x | 2x |
| Sun, 05 Oct 2025 | AU$520.2m | AU$273.6m | -AU$76,816,590.00 | 19.6x | -6.8x | 1.9x |
| Tue, 02 Sep 2025 | AU$503.3m | AU$273.6m | -AU$76,816,590.00 | 17.5x | -6.6x | 1.8x |
| Thu, 31 Jul 2025 | AU$424.7m | AU$272.6m | -AU$65,041,866.00 | 15.6x | -6.5x | 1.6x |
| Sat, 28 Jun 2025 | AU$416.2m | AU$272.6m | -AU$65,041,866.00 | 15.9x | -6.4x | 1.5x |
| Mon, 26 May 2025 | AU$456.4m | AU$272.6m | -AU$65,041,866.00 | 13.7x | -7x | 1.7x |
| Wed, 23 Apr 2025 | AU$398.8m | AU$272.6m | -AU$65,041,866.00 | 14.1x | -6.1x | 1.5x |
| Fri, 21 Mar 2025 | AU$463.5m | AU$272.6m | -AU$65,041,866.00 | 14.6x | -7.1x | 1.7x |
| Sun, 16 Feb 2025 | AU$501.0m | AU$253.8m | -AU$57,118,384.00 | 16.7x | -8.8x | 2x |
| Tue, 14 Jan 2025 | AU$579.6m | AU$253.8m | -AU$57,118,384.00 | 18.6x | -10.1x | 2.3x |
| Thu, 12 Dec 2024 | AU$585.3m | AU$263.5m | -AU$69,135,603.00 | 19.8x | -8.5x | 2.2x |
| Sat, 09 Nov 2024 | AU$637.3m | AU$263.5m | -AU$69,135,603.00 | 20.8x | -9.2x | 2.4x |
| Mon, 07 Oct 2024 | AU$733.2m | AU$263.5m | -AU$69,135,603.00 | 27.5x | -10.6x | 2.8x |
| Wed, 04 Sep 2024 | AU$667.7m | AU$264.1m | -AU$69,597,222.00 | 18.8x | -9.6x | 2.5x |
| Fri, 02 Aug 2024 | AU$653.3m | AU$246.1m | -AU$49,506,434.00 | 24.1x | -13.2x | 2.7x |
| Sun, 30 Jun 2024 | AU$601.6m | AU$246.1m | -AU$49,506,434.00 | 31x | -12.2x | 2.4x |
| Tue, 28 May 2024 | AU$556.8m | AU$246.1m | -AU$49,506,434.00 | 22.6x | -11.2x | 2.3x |
| Thu, 25 Apr 2024 | AU$555.4m | AU$246.1m | -AU$49,506,434.00 | 19.1x | -11.2x | 2.3x |
| Sat, 23 Mar 2024 | AU$519.8m | AU$246.1m | -AU$49,506,434.00 | 13.7x | -10.5x | 2.1x |
| Mon, 19 Feb 2024 | AU$496.5m | AU$248.2m | -AU$39,797,313.00 | 23.6x | -12.5x | 2x |
| Wed, 17 Jan 2024 | AU$464.1m | AU$248.2m | -AU$39,797,313.00 | 24.2x | -11.7x | 1.9x |
| Fri, 15 Dec 2023 | AU$542.9m | AU$248.6m | -AU$52,451,569.00 | 22.2x | -10.4x | 2.2x |
| Sun, 12 Nov 2023 | AU$548.0m | AU$248.6m | -AU$52,451,569.00 | 19.7x | -10.4x | 2.2x |
| Tue, 10 Oct 2023 | AU$555.7m | AU$248.6m | -AU$52,451,569.00 | 22.5x | -10.6x | 2.2x |
| Thu, 07 Sep 2023 | AU$572.2m | AU$248.8m | -AU$52,451,569.00 | 22.7x | -10.9x | 2.3x |
Price to Earnings Ratio
-10.9x
Current Industry PE
- Investors are optimistic on the Australian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 2.1x is lower than the industry's current PS ratio of 2.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have improved over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.
Industry Comparison
How does Australian Clinical Research and Equipment compare with similar industries?
| AU Market | 0.22% | |
| Healthcare | -0.26% | |
| Life Sciences | -5.93% | |
| Clinical Research and Equipment | -5.93% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BLS BLS Pharmaceuticals | AU$1.06 | 14.0% +AU$29.9m | 120.8% | PE27.3x | |
| GSS Genetic Signatures | AU$0.095 | 30.1% +AU$5.0m | -67.2% | PS1.1x | |
| TRJ Trajan Group Holdings | AU$0.20 | 13.9% +AU$3.8m | -77.7% | PS0.2x | |
| VFY Vitrafy Life Sciences | AU$3.85 | 1.3% +AU$3.8m | 195.0% | PS1403.7x |